Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
- PMID: 26534966
- PMCID: PMC5027962
- DOI: 10.1158/1078-0432.CCR-15-0491
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Abstract
Purpose: Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of metastatic melanoma but not studied in children until this phase I protocol.
Experimental design: This study examined safety, pharmacokinetics, and immunogenicity, and immune correlates of ipilimumab administered to subjects ≤21 years old with recurrent or progressive solid tumors. Dose escalation cohorts received 1, 3, 5, or 10 mg/m(2) intravenously every 3 weeks in a 3 + 3 design. Response was assessed after 6 weeks and 12 weeks, and then every 3 months. Treatment was continued until disease progression or unacceptable toxicity.
Results: Thirty-three patients received 72 doses of ipilimumab. Patients enrolled had melanoma (n = 12), sarcoma (n = 17), or other refractory solid tumors (n = 4). Immune-related adverse events included pancreatitis, pneumonitis, colitis, endocrinopathies, and transaminitis with dose-limiting toxicities observed at 5 and 10 mg/kg dose levels. Pharmacokinetics revealed a half-life of 8 to 15 days. At day 21, subjects had increased levels of cycling T cells, but no change in regulatory T-cell populations. Six subjects had confirmed stable disease for 4 to 10 cycles (melanoma, osteosarcoma, clear cell sarcoma, and synovial sarcoma).
Conclusions: Ipilimumab was safely administered to pediatric patients using management algorithms for immune-related toxicities. The spectrum of immune-related adverse events is similar to those described in adults; however, many of the pediatric toxicities were evident after a single dose. Although no objective tumor regressions were observed with ipilimumab as a single agent, subjects with immune-related toxicities had an increased overall survival compared with those who showed no evidence of breaking tolerance.
©2015 American Association for Cancer Research.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5027962/bin/nihms735794f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5027962/bin/nihms735794f2.gif)
Similar articles
-
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17. Lancet Oncol. 2017. PMID: 28729151 Clinical Trial.
-
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.J Immunother Cancer. 2021 Jul;9(7):e002446. doi: 10.1136/jitc-2021-002446. J Immunother Cancer. 2021. PMID: 34301808 Free PMC article. Clinical Trial.
-
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31. Lancet Oncol. 2017. PMID: 28373007 Free PMC article. Clinical Trial.
-
Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Pharmacol Res. 2012. PMID: 21930211 Review.
-
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.Semin Oncol. 2010 Oct;37(5):440-9. doi: 10.1053/j.seminoncol.2010.09.004. Semin Oncol. 2010. PMID: 21074058 Review.
Cited by
-
Off-label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center.Cancer Med. 2024 Apr;13(8):e7154. doi: 10.1002/cam4.7154. Cancer Med. 2024. PMID: 38629258 Free PMC article.
-
Pediatric Solid Cancers: Dissecting the Tumor Microenvironment to Improve the Results of Clinical Immunotherapy.Int J Mol Sci. 2024 Mar 12;25(6):3225. doi: 10.3390/ijms25063225. Int J Mol Sci. 2024. PMID: 38542199 Free PMC article. Review.
-
Intelligent structure prediction and visualization analysis of non-coding RNA in osteosarcoma research.Front Oncol. 2024 Mar 12;14:1255061. doi: 10.3389/fonc.2024.1255061. eCollection 2024. Front Oncol. 2024. PMID: 38532928 Free PMC article.
-
Strategies to overcome low MHC-I expression in paediatric and adult tumours.Immunother Adv. 2023 Dec 11;4(1):ltad028. doi: 10.1093/immadv/ltad028. eCollection 2024. Immunother Adv. 2023. PMID: 38223409 Free PMC article. Review.
-
Immune checkpoint inhibitors in sarcomas: a systematic review.Immunooncol Technol. 2023 Sep 28;20:100407. doi: 10.1016/j.iotech.2023.100407. eCollection 2023 Dec. Immunooncol Technol. 2023. PMID: 38192615 Free PMC article. Review.
References
-
- Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6. - PubMed
-
- Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26:5275–83. - PubMed
-
- Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet Oncology. 2010;11:155–64. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical